eligibility_summary
Key eligibility: Adults (≥18) with unresectable/metastatic pancreatic or bile duct cancer after 1–2 chemo lines, measurable disease (RECIST 1.1), EX02+ tumor, ECOG 0–1, life expectancy >3 mo, negative pregnancy test/contraception, adequate hematologic and organ function. Exclude: active viral infections/AIDS, pregnancy/lactation, planned HIPEC, recent steroids/immunosuppression, active infection, autoimmune/CNS disease, cardiac/respiratory disease, uncontrolled illness, other active cancer, prior CAR/TCR.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: EX02 CAR-T cells (autologous, gene-modified T-cell therapy) given intratumorally or intraperitoneally, with possible IV infusion after lymphodepletion. Mechanism: patient T cells are engineered with a chimeric antigen receptor to bind EX02 on tumor-cell membranes, triggering T-cell activation, cytotoxicity, and cytokine release to eliminate EX02+ cancer cells. Conditioning: fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) to promote CAR-T expansion/persistence. Targets: EX02-positive pancreatic/bile duct tumor cells, T-cell activation pathways.